Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JUOLN
ADC Name
MDX-1203
Synonyms
MDX1203; MDX 1203; BMS-936561; BMS936561; BMS 936561
   Click to Show/Hide
Organization
Medarex, Inc.; Bristol Myers Squibb Co.
Drug Status
Terminated in phase 1
Indication
In total 3 Indication(s)
Kidney cancer [ICD11:2C90-2C91]
Terminated in phase 1
Non Hodgkin lymphoma [ICD11:2B33]
Terminated in phase 1
Renal cell carcinoma [ICD11:2C90]
Terminated in phase 1
Drug-to-Antibody Ratio
2
Structure
Antibody Name
MDX-1115
  Antibody Info 
Antigen Name
CD70 antigen (CD70)
  Antigen Info 
Payload Name
Seco-MED-A
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Mal-Val-Cit
  Linker Info 
Puchem SID
381127695
DrugMap ID
DM0RIQF
TTD ID
D03KLF
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT00944905
Phase 1
A phase 1, multicenter, open-label, dose-escalation, multidose study of MDX-1203 in subjects with advanced/recurrent clear cell renal cell carcinoma or relapsed/refractory B-cell non Hodgkin's lymphoma.

   Click to Show/Hide
Undisclosed  NCT00944905
Phase 1
A phase 1, multicenter, open-label, dose-escalation, multidose study of MDX-1203 in subjects with advanced/recurrent clear cell renal cell carcinoma or relapsed/refractory B-cell non Hodgkin's lymphoma.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Advanced or recurrent clear cell renal cell carcinoma (ccRCC) or relapsed or refractory B-non Hodgkin lymphoma (NHL), life expectancy of 12 weeks; ECOG performance status of 0-2; measurable disease by RECIST 1.1 criteria for ccRCC and by IWG 2007 criteria for B-NHL as well as adequate hematologic, renal and liver function parameters.
Administration Dosage
0.50, 1.00, 2.00, 4.00, 8.00, 15.00 mg/kg administered every 21 days in a 42 day cycle for a maximum of 17 cycles, IV.
Related Clinical Trial
NCT Number NCT00944905  Clinical Status Phase 1
Clinical Description A phase 1, multicenter, open-label, dose-escalation, multidose study of MDX-1203 in subjects with advanced/recurrent clear cell renal cell carcinoma or relapsed/refractory B-cell non Hodgkin's lymphoma.
Primary Endpoint
The highest best tolerated dose and the recommended dose for future studies was 8 mg/kg dose.There was no MTD determined during the acute toxicity assessment window according to protocol-defined DLT according to protocol-defined DLT. There was disease stabilization in 18 of 26 patients (69.23%) without correlation with received dose.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT00944905  Clinical Status Phase 1
Clinical Description A phase 1, multicenter, open-label, dose-escalation, multidose study of MDX-1203 in subjects with advanced/recurrent clear cell renal cell carcinoma or relapsed/refractory B-cell non Hodgkin's lymphoma.
References
Ref 1 First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016 Jan;77(1):155-62.
Ref 2 A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.